MX2015008888A - Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido. - Google Patents

Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido.

Info

Publication number
MX2015008888A
MX2015008888A MX2015008888A MX2015008888A MX2015008888A MX 2015008888 A MX2015008888 A MX 2015008888A MX 2015008888 A MX2015008888 A MX 2015008888A MX 2015008888 A MX2015008888 A MX 2015008888A MX 2015008888 A MX2015008888 A MX 2015008888A
Authority
MX
Mexico
Prior art keywords
treating cancer
level
nucleoside transporter
cancer based
nucleoside
Prior art date
Application number
MX2015008888A
Other languages
English (en)
Inventor
Carla Heise
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of MX2015008888A publication Critical patent/MX2015008888A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona métodos y composiciones para tratar el cáncer administrando a) una composición que comprende nanopartículas que comprenden paclitaxel y una albúmina y b) un análogo de nucleósido (por ejemplo, gemcitabina) basado en los niveles de un transportador de nucleósido (por ejemplo, hENT1).
MX2015008888A 2013-01-11 2014-01-10 Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido. MX2015008888A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361848780P 2013-01-11 2013-01-11
US201361752397P 2013-01-14 2013-01-14
US13/794,486 US20140199404A1 (en) 2013-01-11 2013-03-11 Method for treating cancer based on level of a nucleoside transporter
PCT/US2014/011006 WO2014110345A1 (en) 2013-01-11 2014-01-10 Method for treating cancer based on level of a nucleoside transporter

Publications (1)

Publication Number Publication Date
MX2015008888A true MX2015008888A (es) 2015-11-13

Family

ID=51165318

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008888A MX2015008888A (es) 2013-01-11 2014-01-10 Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido.

Country Status (7)

Country Link
US (1) US20140199404A1 (es)
EP (1) EP2943191A4 (es)
JP (1) JP2016513075A (es)
CA (1) CA2897673A1 (es)
HK (1) HK1217180A1 (es)
MX (1) MX2015008888A (es)
WO (1) WO2014110345A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1585548T3 (en) 2002-12-09 2018-09-03 Abraxis Bioscience Llc COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
KR20140016402A (ko) 2005-02-18 2014-02-07 아브락시스 바이오사이언스, 엘엘씨 치료제의 조합 및 투여 방식, 및 조합 요법
PT3311805T (pt) 2005-08-31 2020-04-21 Abraxis Bioscience Llc Composições compreendendo agentes farmacêuticos pouco hidrossolúveis e agentes antimicrobianos
DK2117520T3 (en) 2006-12-14 2019-01-07 Abraxis Bioscience Llc BREAST CANCER THERAPY BASED ON HORMON RECEPTOR STATUS WITH NANOPARTICLES INCLUDING TAXAN
US8927019B2 (en) * 2007-06-01 2015-01-06 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
PL2419732T3 (pl) 2009-04-15 2020-05-18 Abraxis Bioscience, Llc Kompozycje nanocząstek wolnych od prionów i sposoby ich wytwarzania
ES2580135T3 (es) 2010-03-26 2016-08-19 Abraxis Bioscience, Llc Métodos de tratamiento de carcinoma hepatocelular
CA2793974A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Methods of treating cancer
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
KR20180049180A (ko) 2010-06-04 2018-05-10 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
WO2012149451A1 (en) 2011-04-28 2012-11-01 Abraxis Bioscience, Llc Intravascular delivery of nanoparticle compositions and uses thereof
KR20140107417A (ko) 2011-12-14 2014-09-04 아브락시스 바이오사이언스, 엘엘씨 입자의 동결건조 또는 동결을 위한 중합체 부형제의 용도
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
CN105228612A (zh) 2013-03-12 2016-01-06 阿布拉科斯生物科学有限公司 治疗肺癌的方法
CN105246468A (zh) 2013-03-14 2016-01-13 阿布拉科斯生物科学有限公司 治疗膀胱癌的方法
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
SI3313401T1 (sl) 2015-06-29 2022-04-29 Abraxis Bioscience, Llc Nanodelci, ki vsebujejo sirolim in albumin, za uporabo pri zdravljenju tumorjev epiteloidnih celic
US11371099B2 (en) 2015-11-30 2022-06-28 Mayo Foundation For Medical Education And Research HEATR1 as a marker for chemoresistance
JP2019529520A (ja) * 2016-10-07 2019-10-17 アブラクシス バイオサイエンス， エルエルシー 胆道がんを処置する方法
AU2018312224A1 (en) 2017-07-31 2020-02-27 January Therapeutics, Inc. Organophosphate derivatives
SG11202009145PA (en) 2018-03-20 2020-10-29 Abraxis Bioscience Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
US11708637B2 (en) * 2019-08-13 2023-07-25 The Regents Of The University Of California Methods of supporting a graphene sheet disposed on a frame support
EP4051241A4 (en) 2019-10-28 2023-12-06 Abraxis BioScience, LLC PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMYCIN

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200204907B (en) * 2001-06-26 2003-03-03 Univ Nat Taiwan Collapsin Response Mediator Protein-1.
KR20140016402A (ko) * 2005-02-18 2014-02-07 아브락시스 바이오사이언스, 엘엘씨 치료제의 조합 및 투여 방식, 및 조합 요법
KR20130028727A (ko) * 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
US20130005678A1 (en) * 2010-03-30 2013-01-03 Clavis Pharma Asa Methods and Compositions for Treating or Ameliorating Cancer Using Gemcitabine-5'-Elaidate
MX343671B (es) * 2010-06-02 2016-11-16 Abraxis Bioscience Llc * Metodos de tratamiento de cancer de vejiga.
US20130116209A1 (en) * 2011-08-02 2013-05-09 Ventana Medical Systems, Inc. Method for selection of chemotherapeutic agents for adenocarcinoma cancer

Also Published As

Publication number Publication date
CA2897673A1 (en) 2014-07-17
US20140199404A1 (en) 2014-07-17
WO2014110345A1 (en) 2014-07-17
EP2943191A4 (en) 2016-07-13
EP2943191A1 (en) 2015-11-18
JP2016513075A (ja) 2016-05-12
HK1217180A1 (zh) 2016-12-30

Similar Documents

Publication Publication Date Title
MX2015008888A (es) Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido.
MX2015008889A (es) Metodo para tratar cancer con base en el estado de la mutacion k-ras.
MX2021002455A (es) Metodos para tratar tumores de celulas epitelioides.
MX2015011753A (es) Metodos para tratar cancer de vegija.
CL2018000429A1 (es) Moduladores de la expresión de kras
PH12016502066A1 (en) Methods of treating bladder cancer
MX2022015755A (es) Profarmacos de hormona paratiroidea (pth).
MX2015011752A (es) Metodos para tratar cancer de pulmon.
MX2023013010A (es) Composiciones con nanoparticulas que comprenden sirolimus y albumina para usarse en el tratamiento de cancer relacionado con una aberracion activante de m-tor.
MX2018005829A (es) Composiciones para tratar el cabello.
MX2020009223A (es) Anticuerpos anti-fgfr2iiib afucosilados.
MX2017002852A (es) Activacion de linfocitos que infiltran la medula en condiciones hipoxicas alternando con normoxicas.
CR20160418A (es) Nuevos compuestos biciclicos de 7 eslabones
MX2015008898A (es) Metodos para el tratamiento de cancer pancreatico.
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX2015011783A (es) Metodos para tratar tumores solidos pediatricos.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
IL288342A (en) Formulations and methods for lyophilic nanoparticulate forms
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
PH12017501879A1 (en) Methods for treating cancer
PH12017501864A1 (en) Compositions and methods for treating autism
MX2018003678A (es) Metodos moleculares de aseguramiento de la calidad para su uso en la secuenciacion.
MX2016015568A (es) Derivados de nucleosidos para el tratamiento del cancer.
MX2015013021A (es) 5-bromo-indirrubinas.
MX2021008225A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.